Atea Pharmaceuticals Third Quarter 2026 Financial Results Conference Call - ATEA PHARMACEUTICALS INC

Financial Performance:

• Cash and marketable securities totaled $191.2 million as of September 30, 2026.
• Executed a non-dilutive credit facility with Hercules Capital for up to $200 million; $65 million drawn at closing on November 6, 2026.
• The credit facility extends the cash runway through mid-2028 and is expected to fund operations until profitability.
• Research and Development expenses decreased in the first nine months of 2026 due to reduced external spend on HCV Phase III trials and lower stock-based compensation, partially offset by increased HEV preclinical activities.
• General and Administrative expenses decreased driven by lower salaries, wages, and professional fees.
• Management projects the credit facility will be sufficient for U.S. commercial launch efforts, eliminating the need for additional equity financing.

Guidance and Future Outlook:

• Targeting top-line results for the global C-Forward trial in early 2027.
• Aiming for New Drug Application (NDA) submission to the FDA by mid-2027, pending positive data from C-Beyond and C-Forward.
• Anticipates U.S. commercial launch of Bem-Resosvir (BAM-RZR) in 2028.
• HEV program (AT587): Single ascending dose complete; multiple ascending dose in progress; Proof-of-Concept study targeted for H1 2027 with preliminary results expected late 2027.
• Management projects peak U.S. net sales potential for Bem-Resosvir exceeding $700 million annually.

Business Segments and Product Lines:

• HCV (Bem-Resosvir): Phase 3 C-Beyond trial met primary and secondary endpoints (non-inferiority vs. Epclusa); 94% SVR rate for non-cirrhotic patients on 8-week regimen vs. 95% for 12-week standard.
• HEV (AT587): Potential first-in-class direct-acting antiviral; initiated Phase 1 in HCV subjects (corrected from transcript context: "HAL-C" likely refers to Hepatitis E) and healthy volunteers; addresses chronic HEV in immunocompromised patients with no current FDA-approved treatments.
• Product Profile: Bem-Resosvir offers 8-week treatment for non-cirrhotics, protease inhibitor-free composition, low drug-drug interaction risk, and no food effects.
• Commercial Readiness: Manufacturing processes in place; preparing a focused sales force of 75–100 specialists to target ~7,800 prescribers.

Market and Competitive Landscape:

• Global HCV net sales approx. $2.6 billion in 2025; U.S. share approx. $1.3 billion.
• Market dynamics show a widening gap: only ~50% of newly diagnosed patients are treated annually, with a growing untreated pool estimated at 4 million in the U.S.
• Strong uptake potential predicted: 76% of high-volume GDA prescribers indicated they would be extremely likely to prescribe Bem-Resosvir.
• Market expansion strategy focuses on "test-and-treat" models to convert untreated diagnosed patients rather than just competing for existing market share.
• Current market split estimated at 50% Medicaid/Medicare and 50% commercial.

Risks and Challenges:

• Regulatory: FDA approval and NDA acceptance are pending; successful global data package relies on C-Forward results.
• Legislative: Expectation that the HCV elimination bill sponsored by Senator Cassidy will not advance in the current Congress without its original sponsor, requiring reintroduction in 2027.
• Commercial: Uncertainty regarding managed care uptake, payer formulary positioning, and potential impacts from government legislation (e.g., Inflation Reduction Act, Medicaid changes).
• Clinical: AT587 Phase 1 results are preliminary; future Proof-of-Concept study data is required to validate efficacy in infected subjects.

Management Commentary and Tone:

• Tone is highly confident and optimistic, emphasizing a "solid financial position" and a "milestone-rich 2027."
• Management rejects the narrative of a declining HCV market, citing a growing pool of untreated patients and the potential for market expansion.
• Emphasis placed on the "best-in-class" potential of Bem-Resosvir due to short treatment duration and low interaction profile compared to standard of care.
• Clear strategic pivot toward commercial readiness and value creation ahead of the 2028 launch.

Analyst Questions and Answers:

• Payer Strategy: Management confirmed no formal payer discussions have begun; current focus is on assessing the landscape (commercial, Medicare, Medicaid) to prepare for post-approval formulary negotiations.
• Capital Sufficiency: Confirmed the $200M credit facility is sufficient to fund commercial launch and clinical programs without needing equity raises.
• HEV Study Design: Clarified that both single and multiple ascending dose phases of AT587 are in healthy volunteers; PD data in infected subjects will come from a future Phase 1b Proof-of-Concept study.
• Government Payer Impact: Acknowledged movements in government programs but maintained that the untreated patient pool is expanding, creating a sustained addressable market.

Other Key Points:

• Transcript mentions specific patient demographics in C-Beyond, including high rates of concomitant medication use (89%), psychiatric disorders (2/3), and injection drug use (over 50%).
• No serious adverse events were related to Bem-Resosvir; 3 deaths in the control arm (Sofvel) were not drug-related.
• The company is leveraging a "test-and-treat" care model to reduce patient attrition and treatment delays.
• Manufacturing cost of goods is expected to be low relative to net pricing.